The Safety of Lovastatin in Patients with Non-Alcoholic Fatty Liver Disease

Abstract

Statins have wide use in medical practice, being considered the first line of lipogenic agents. Also, the statin's pleiotropic effects and efficacy in non-alcoholic fatty liver disease are known, the most frequent adverse effect is represented by the increase of the transaminases. On a group of 28 patients with non-alcoholic fatty liver disease, treated for 3 months with Lovastatin 20 mg, we followed the transaminases and bilirubin values at the beginning and at the end of the treatment. The patients with transaminases values over three times the upper normal values were not included. The obtained results show the non-inferiority of the Lovastatin reported to control. No adverse reactions were recorded, and the transaminase values were maintained.